


Medtronic

Mosaic Neo™ mitral bioprosthesis


Intuitive by design.
Proven to perform.



Created for LVOT clearance

With its atrialized design, wide anterior interstrut distance and clear orientation cuff markers, the Mosaic Neo valve offers a unique set of features to help enable clearance of the left ventricular outflow tract (LVOT).





The native-porcine difference

The native-porcine design of the Mosaic Neo valve offers one wider leaflet spaced at 135° - this wider interstrut distance at the anterior annulus is designed to enable LVOT clearance and accommodate ventricular flow.^{†,1-3}



Atrialized design

The atrialized design of the Mosaic Neo valve reduces left ventricular (LV) protrusion by up to 23% compared to the Mosaic™ mitral valve.^{†,4,5}



Radiopaque inflow marker

Provides an easy-to-identify landing zone for transcatheter mitral valve-in-valve procedures.⁶


[†] Bench test, may not be indicative of clinical performance.

Enhanced for ease

The Mosaic Neo™ platform offers multiple enhancements designed to enable a straightforward mitral valve replacement procedure. Updated smooth-barrel sizers, the Cinch™ mechanism, and a quick-detach handle release work together to simplify workflow – delivering a smooth implant experience from start to finish.

Cinch™ implant system

- Facilitates valve implantation particularly through tight patient anatomy and small incisions.⁷
- Helps prevent suture looping.⁷
- Designed to protect the tissue from inadvertent damage.⁸



Quick-detach handle removal

- Eliminates the need to unscrew the handle.^{8,9}
- A single-cut handle release for quick detachment and a simplified implantation process.^{8,9}




Simplified sizers

- Pre-attached smooth barrel sizers offer a simple mitral annular measurement.^{6,9}




Streamlined for minimally invasive

With the small incision sizers and the low implant profile, the Mosaic Neo valve sets a new benchmark for ease of use in small incision surgery,⁹ offering an implant profile which is reduced up to 40% versus other commercially available tissue mitral valves.^{‡,10-12}



Reduced implant profile

Best-in-class implant profile^{‡,10-12}



**Mosaic Neo™
mitral valve**

Size 29

Implant profile height:
21.00 mm

**MITRIS RESILIA™*
mitral valve**

Size 27

Implant profile height:
26.40 mm

**Epic™* Plus
mitral valve**

Size 29

Implant profile height:
34.90 mm

[‡] Dimensional measurements taken with Mosaic Neo valve size 29, Epic™* Plus size 29, MITRIS RESILIA™* size 27 based on OD comparability.



Proven to perform

A next-generation valve offering industry-leading, unsurpassed durability and excellent hemodynamics as demonstrated by the Mosaic mitral valve.^{13,15-18}

The Mosaic Neo valve carries forward a legacy of performance surgeons have trusted for decades – now enhanced for the future.

Over half a million patients served with the AOA™ tissue treatment



The Mosaic Neo valve benefits from AOA treatment, which reduces calcification in the tissue leaflets and is designed to enhance long-term valve durability as supported by more than 30 years of its clinical use encompassing over half a million patients.^{§,14, 19-21}

[§] The benefits of AOA tissue treatment have been demonstrated through animal testing. No direct clinical evaluation of the benefits of AOA treatment in humans has been conducted.

Key risks associated with the use of bioprosthetic heart valves include: structural deterioration, nonstructural dysfunction, and endocarditis.




Ordering information

Order number	A Valve size (mm) (stent O.D. ^Ω)	B Orifice diameter (mm) (stent I.D.)	C Suture ring diameter (mm)	D Valve height (mm)	E Ventricular protrusion (mm)
310MN25	25	22.5	33.5	18.0	11.0
310MN27	27	24.0	35.5	19.0	11.5
310MN29	29	26.0	38.0	20.5	12.5
310MN31	31	28.0	41.0	22.0	14.0
310MN33	33	30.0	43.5	23.0	14.5

Accessories

Item number	Description
7639	Handle (234 mm length), to be used with Mosaic™ and Mosaic Neo™ bioprostheses
7639XL	XL Handle (368 mm length), to be used with Mosaic™ and Mosaic Neo™ bioprostheses
S310MNH	Mosaic Neo™ mitral sizers
T310MNH	Tray for Mosaic Neo™ mitral sizers
S310MNS	Mosaic Neo™ mitral small incision sizers
T310MNS	Tray for Mosaic Neo™ mitral small incision sizers



- A** = Valve size (stent O.D.^Ω)
- B** = Orifice diameter (stent I.D.)
- C** = Suture ring diameter
- D** = Valve height
- E** = Ventricular protrusion

Nominal values in millimeters

^Ω Stent O.D. equivalent to annulus diameter.

References

1. Brunel L, Williams ZA, Beijerink NJ, et al. Bioprosthetic interstrut distance subtending the preserved anterior mitral leaflet mitigates left ventricular outflow tract obstruction. *JTCVS Open*. May 21, 2021;8:251-258.
2. Medtronic data on file. D00807486 Rev. A. Valve Dimensional Measurements Report.
3. Medtronic data on file. D00807491 Rev. A. Valve Anatomical Models.
4. M064035C001. Mosaic Neo Mitral Bioprosthesis Instructions for Use.
5. Medtronic data on file. D01442020 Rev. A. Stent Post Protrusion Design Characterization Report.
6. Medtronic data on file. D01433947 Rev. B, Attachment B. Design Validation Report.
7. Takagi K, Arinaga K, Takaseya T, et al. Hemodynamic and clinical performance of the 25-mm Medtronic Mosaic porcine bioprosthesis in the mitral position. *J Artif Organs*. March 2022;25(1):34-41.
8. Medtronic data on file. D01187247 Rev. E. Design Description Document.
9. Medtronic data on file. Mosaic Neo Mitral Bioprosthesis Claims Matrix, REF-33133. Design Validation Surgeon Survey.
10. Medtronic data on file. Report D01541798 Rev. A. Design Characterization Report.
11. Medtronic data on file. Report D01566568 Rev. A. Design Characterization Report.
12. Medtronic data on file. Report D01576936 Rev. A. Design Characterization Report.
13. Rieß FC, Fradet G, Lavoie A, Leggett M. Long-Term Outcomes of the Mosaic Bioprosthesis. *Ann Thorac Surg*. March 2018;105(3):763-769.
14. Weber PA, Jouan J, Matsunaga A, et al. Evidence of mitigated calcification of the Mosaic versus Hancock Standard valve xenograft in the mitral position of young sheep. *J Thorac Cardiovasc Surg*. November 2006;132(5):1137-1143.
15. Beute TJ, Goehler M, Parker J, et al. Long-Term Outcomes of Mosaic Versus Perimount Mitral Replacements: 17-Year Follow-Up of 940 Implants. *Ann Thorac Surg*. August 2020;110(2):508-515.
16. Malvindi PG, Mastro F, Kowalewski M, et al. Durability of Mitral Valve Bioprostheses: A Meta-Analysis of Long-Term Follow-up Studies. *Ann Thorac Surg*. February 2020;109(2):603-611.
17. Riess FC, Cramer E, Hansen L, et al. Clinical results of the Medtronic Mosaic porcine bioprosthesis up to 13 years. *Eur J Cardiothorac Surg*. January 2010;37(1):145-153.
18. Tomšič A, Marin-Cuartas M, De La Cuesta M, et al. Clinical Outcomes After Mitral Valve Replacement With Epic and Mosaic Bioprosthetic Valves. *Ann Thorac Surg Short Rep*. December 21, 2023;2(2):251-256.
19. Girardot MN, Girardot JM, Schoen FJ. Development of the AOA process as antimicrobial treatment for bioprosthetic heart valves. *Trans Soc Biomat*. 1993;16:266.
20. Girardot MN, Torrianni M, Girardot JM. Effect of AOA on glutaraldehyde-fixed bioprosthetic heart valve cusps and walls: binding and calcification studies. *Int J Artif Organs*. February 1994;17(2):76-82.
21. Gott JP, Pan-Chih, Dorsey LM, et al. Calcification of porcine valves: a successful new method of antimicrobialization. *Ann Thorac Surg*. February 1992;53(2):207-216.

Important Safety Information

Mosaic Neo mitral bioprosthesis

Indications: The Mosaic Neo mitral bioprosthesis is indicated for the replacement of a malfunctioning native or prosthetic mitral heart valve.

Contraindications: No contraindications for use of this device are known.

Warnings/Precautions/Adverse Events: As with any implanted medical device, there is potential for patient immunological response, including an allergic response. Care should be exercised in patients with hypersensitivities to the device materials, such as nickel. Calcific degeneration could cause accelerated deterioration of the valve in patients with altered calcium metabolism (for example, chronic renal failure, hyperparathyroidism). Calcification may occur earlier in children, adolescents, or young adults. Premature calcification may also occur in older adults who accept a biologic prosthesis. Patients with a bioprosthesis that require chronic anticoagulation are at additional risk of bleeding. Stenosis and regurgitation of the bioprosthesis may occur in patients with coagulation disorders such as AT3 deficiency. Paravalvular leak is more likely to occur in patients with aneurysmal aortic or degenerative conditions, cystic medial necrosis, or Marfan syndrome. Adverse events can include: allergic reaction/immunologic response, aneurysm or pseudoaneurysm, aortic tissue damage, cardiac arrest, cardiac arrhythmias, cardiac tamponade, embolism or thromboembolism, endocarditis, heart block, heart failure, hemodynamic instability, hemolysis, hemolytic anemia, anticoagulant/antiplatelet-related hemorrhage, hypertension or hypotension, inflammatory reaction, infection other than endocarditis, transvalvular or paravalvular leak, mitral tissue damage, myocardial infarction, nonstructural dysfunction (leaflet entrapment/impingement, obstructive pannus ingrowth, suture dehiscence, inappropriate sizing), pericardial effusion, pleural effusion, prosthesis regurgitation, prosthesis stenosis, stroke, structural deterioration (calcification, leaflet tear), thrombus or thrombosis. These complications could lead to reoperation, explant of the bioprosthesis, permanent disability or organ damage, or death.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (IFU). If applicable, consult electronic IFUs (eIFUs) at www.medtronic.com/manuals. Note: eIFUs can be viewed using a current version of any major internet browser.

Mosaic mitral bioprosthesis

Indications: For the replacement of malfunctioning native or prosthetic mitral heart valves.

Contraindications: None known.

Warnings/Precautions/Adverse Events: Accelerated deterioration due to calcific degeneration of bioprosthesis may occur in children, adolescents, young adults, and patients with altered calcium metabolism (e.g., chronic renal failure, hyperparathyroidism). Adverse events can include angina, cardiac arrhythmia, cardiac dysrhythmias, death, endocarditis, infection other than endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, transvalvular or paravalvular leak, myocardial infarction, nonstructural dysfunction, stroke, structural deterioration, thromboembolism, or valve thrombosis.

Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.

For a list of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the instructions for use. For countries that use (electronic instructions for use) eIFUs, consult instructions for use at this website medtronic.com/manuals.

Medtronic

710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA
Tel: (763) 514-4000
Fax: (763) 514-4879

Toll-free 1 (800) 328-2518
(24-hour technical support for
physicians and medical professionals)

medtronic.com

©2026 Medtronic. All rights reserved. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic.™™Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

US-CV-2600251 v1.0
03/2026